Associated Papers
The Role of Pharmacogenetic Biomarkers in Pain.
Martin da Silva I et al.
Biomedicines, 2025
Mathematical modeling of pharmacokinetics and pharmacodynamics of losartan in relation to CYP2C9 allele variants.
Babaev D et al.
Frontiers in Systems Biology, 2025
Application of rapid genotyping of Warfarin individualized pharmacogenetic variants in Warfarin therapy.
Huang D et al.
Scientific Reports, 2024
Distribution of the cytochrome P450 *alleles for CYP2C9 and CYP2C19 in a cohort of the Danish Blood Donor Study determined by using the Illumina Infinium Global Screening Array.
Jørgensen S et al.
Basic & Clinical Pharmacology & Toxicology, 2024
The genetic landscape of major drug metabolizing cytochrome P450 genes-an updated analysis of population-scale sequencing data.
Zhou Y et al.
The Pharmacogenomics Journal, 2022
Gene Polymorphism of Biotransformation Enzymes and Ciprofloxacin Pharmacokinetics in Pediatric Patients with Cystic Fibrosis.
Zyryanov SK et al.
Biomedicines, 2022
CYP2C9 and CYP2C19: Deep Mutational Scanning and Functional Characterization of Genomic Missense Variants.
Zhang L et al.
Clinical and Translational Science, 2020
Role of Genetic Variations in the Hepatic Handling of Drugs.
Marin JJG et al.
International Journal of Molecular Sciences, 2020
Defining screening panel of functional variants of CYP1A1, CYP2C9, CYP2C19, CYP2D6, and CYP3A4 genes in Serbian population.
Skadrić I et al.
International Journal of Legal Medicine, 2020
Assessment of pharmacogenomic SLCO1B1 assay for prediction of neuromuscular pain in type 2 diabetes mellitus and cardiovascular patients: preliminary results.
Licito A et al.
European Review for Medical and Pharmacological Sciences, 2020
CYP2C9, CYP2C19, CYP2D6 and CYP3A5 polymorphisms in South-East and East Asian populations: A systematic review.
Dorji PW et al.
Journal of Clinical Pharmacy and Therapeutics, 2019
Personalized rosuvastatin therapy in problem patients with partial statin intolerance.
Shek AB et al.
Archives of Medical Sciences. Atherosclerotic Diseases, 2018
Pharmacogenomics of CYP2C9: Functional and Clinical Considerations.
Daly AK et al.
Journal of Personalized Medicine, 2017
Distribution of CYP2C8 and CYP2C9 amino acid substitution alleles in South Indian diabetes patients: A genotypic and computational protein phenotype study.
Rao DK et al.
Clinical and Experimental Pharmacology & Physiology, 2017
Worldwide Distribution of Cytochrome P450 Alleles: A Meta-analysis of Population-scale Sequencing Projects.
Zhou Y et al.
Clinical Pharmacology and Therapeutics, 2017
Comparison of CYP2C9, CYP2C19, CYP2D6, ABCB1, and SLCO1B1 gene-polymorphism frequency in Russian and Nanai populations.
Sychev DA et al.
Pharmacogenomics and Personalized Medicine, 2017
Harnessing Knowledge on Very Important Pharmacogenes CYP2C9 and CYP2C19 Variation for Precision Medicine in Resource-Limited Global Conflict Zones.
Barlas İÖ et al.
Omics : a Journal of Integrative Biology, 2016
[POLYMORPHISM OF CYP2C9 GENE AND RISK OF HEPATOTOXICITY DEVELOPMENT DURING ANTIRETROVIRAL THERAPY.]
Kurbat MN et al.
Eksperimental'naia I Klinicheskaia Farmakologiia, 2016
Characterization of drug-metabolizing enzymes CYP2C9, CYP2C19 polymorphisms in Tunisian, Kuwaiti and Bahraini populations.
Abdelhedi R et al.
Journal of Genetics, 2015
Genetic determinants of acenocoumarol and warfarin maintenance dose requirements in Slavic population: a potential role of CYP4F2 and GGCX polymorphisms.
Wypasek E et al.
Thrombosis Research, 2014
Advances in molecular modeling of human cytochrome P450 polymorphism.
Martiny VY et al.
Journal of Molecular Biology, 2013
Influence of genetic variations on levels of inflammatory markers of healthy subjects at baseline and one week after clopidogrel therapy; results of a preliminary study.
Shahabi P et al.
International Journal of Molecular Sciences, 2013
Implication of novel CYP2C9*57 (p.Asn204His) variant in coumarin hypersensitivity.
Nahar R et al.
Thrombosis Research, 2013
CYP2C19*17 gain-of-function polymorphism is associated with peptic ulcer disease.
Musumba CO et al.
Clinical Pharmacology and Therapeutics, 2013
CYP2C9 and VKORC1 gene polymorphism is inessential for bleeding development under conditions of oral application of anticoagulant acenocoumarol in Russian patients at high risk of thromboembolic complications.
Sychev DV et al.
Bulletin of Experimental Biology and Medicine, 2012
Association of cytochrome P450 genetic polymorphisms with neoadjuvant chemotherapy efficacy in breast cancer patients.
Seredina TA et al.
Bmc Medical Genetics, 2012
Polymorphic metabolism by functional alterations of human cytochrome P450 enzymes.
Lee IS et al.
Archives of Pharmacal Research, 2011
[CYP2C9 and VKORC1 gene polymorphism and acenocoumarol anticoagulant activity in Russian patients at high risk of thromboembolic complications].
Sychev DA et al.
Vestnik Rossiiskoi Akademii Meditsinskikh Nauk, 2011
Polymorphisms of human cytochrome P450 2C9 and the functional relevance.
Zhou SF et al.
Toxicology, 2010
CYP2C19*2 and CYP2C9*3 alleles are associated with stent thrombosis: a case-control study.
Harmsze AM et al.
European Heart Journal, 2010
Genotype frequencies of selected drug metabolizing enzymes and ABC drug transporters among breast cancer patients on FAC chemotherapy.
Afsar NA et al.
Basic & Clinical Pharmacology & Toxicology, 2010
Functional pharmacogenetics/genomics of human cytochromes P450 involved in drug biotransformation.
Zanger UM et al.
Analytical and Bioanalytical Chemistry, 2008
Novel CYP2C9 promoter variants and assessment of their impact on gene expression.
Kramer MA et al.
Molecular Pharmacology, 2008
Pharmacogenetic testing of CYP2C9 and VKORC1 alleles for warfarin.
Flockhart DA et al.
Genetics in Medicine : Official Journal of the American College of Medical Genetics, 2008
CYP2C9 and CYP2C19 polymorphic forms are related to increased indisulam exposure and higher risk of severe hematologic toxicity.
Zandvliet AS et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 2007
Contribution of CYP2C9 to variability in vitamin K antagonist metabolism.
Daly AK et al.
Expert Opinion on Drug Metabolism & Toxicology, 2006
[Implications of pharmacogenetics in every-day practice].
Gerloff T et al.
Der Internist, 2005
Predicting drug response and toxicity based on gene polymorphisms.
Robert J et al.
Critical Reviews in Oncology/hematology, 2005
Clinical consequences of cytochrome P450 2C9 polymorphisms.
Kirchheiner J et al.
Clinical Pharmacology and Therapeutics, 2005
Novel CYP2C9 genetic variants in Asian subjects and their influence on maintenance warfarin dose.
Zhao F et al.
Clinical Pharmacology and Therapeutics, 2004
Discovery of new potentially defective alleles of human CYP2C9.
Blaisdell J et al.
Pharmacogenetics, 2004
Cytochrome P450 pharmacogenetics as a predictor of toxicity and clinical response to pulse cyclophosphamide in lupus nephritis.
Takada K et al.
Arthritis and Rheumatism, 2004
Polymorphisms of drug-metabolizing enzymes CYP2C9, CYP2C19, CYP2D6, CYP1A1, NAT2 and of P-glycoprotein in a Russian population.
Gaikovitch EA et al.
European Journal of Clinical Pharmacology, 2003
Bioactivation of cyclophosphamide: the role of polymorphic CYP2C enzymes.
Griskevicius L et al.
European Journal of Clinical Pharmacology, 2003
Clinical relevance of genetic polymorphisms in the human CYP2C subfamily.
Goldstein JA
British Journal of Clinical Pharmacology, 2001
Molecular modelling of human CYP2C subfamily enzymes CYP2C9 and CYP2C19: rationalization of substrate specificity and site-directed mutagenesis experiments in the CYP2C subfamily.
Lewis DF et al.
Xenobiotica; the Fate of Foreign Compounds in Biological Systems, 1998
[Pharmacogenetics: variability of drug effects and metabolic reactions].
Goedde HW
Der Internist, 1974